-
In Vitro Activities of Enantiopure and Racemic 1 ‘-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
- Back
Metadata
Document Title
In Vitro Activities of Enantiopure and Racemic 1 '-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis
Author
Warit S, Rukseree K, Prammananan T, Hongmanee P, Billamas P, Jaitrong S, Chaiprasert A, Jaki BU, Pauli GF, Franzblau SG, Palittapongarnpim P
Name from Authors Collection
Scopus Author ID
8974555500
Scopus Author ID
55544000600
Affiliations
National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Mahidol University; Mahidol University; Mahidol University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Mahidol University
Type
Article
Source Title
SCIENTIA PHARMACEUTICA
Year
2017
Volume
85
Issue
3
Open Access
Green Submitted, Green Published, gold
Publisher
MDPI
DOI
10.3390/scipharm85030032
Format
Abstract
In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1'-acetoxychavicol acetate (ACA), exhibited marked anti-tuberculosis activity. The minimal inhibition concentrations (MICs) of the S-enantiomer of ACA (S-ACA) against M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294 strains were 0.2 mu g/mL and 0.7 mu g/mL, respectively. More than 95% of 100 drug-sensitive and 50 drug-resistant mycobacterial clinical isolates were inhibited by extracted S-ACA at 1.0 mu g/mL. All of the remaining isolates were inhibited at 2.0 mu g/mL. In contrast to the S-enantiomer, synthetic racemic 1'-R, S-ACA (rac-ACA) showed MICs of 0.5 mu g/mL and 2.7 mu g/mL for M. tuberculosis H37Ra ATCC 25177 and H37Rv ATCC 27294, respectively, suggesting that the anti-tuberculosis effect might be primarily due to the S-form. These observations were in line with the MICs of rac-ACA against 98% of 93 drug-resistant clinical isolates, which showed the effective inhibitory dose at 2.0 mu g/mL. After exposure to 2.7 mu g/mL of rac-ACA for at least 3 h, the tubercle bacilli were completely killed. These demonstrated that ACA had potent anti-TB activity.
Industrial Classification
Funding Sponsor
National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Ministry of Sciences and Technology, Thailand [P-00_20209]
Publication Source
WOS